Breaking News, Collaborations & Alliances

Ascidian Therapeutics, Forge Biologics Partner to Advance Stargardt Treatment

Forge to provide Ascidian with process and analytical development services, toxicology, and cGMP manufacturing.

Author Image

By: Charlie Sternberg

Associate Editor

Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, and Forge Biologics, a manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, have partnered to advance the development and manufacturing of ACDN-01, Ascidian’s lead retinal program for the treatment of Stargardt disease. Ascidian is currently evaluating ACDN-01 in the Phase 1/2 STELLAR dose-escalation trial. ACDN-01 uses a single AAV vector to perform in vivo&n...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters